{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PD+0360324", "query": { "intervention": "PD 0360324" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T17:19:03.331Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00550355", "title": "Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "PD 0360324", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 78, "start_date": "2007-08", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2009-07-14", "last_synced_at": "2026-09-04T17:19:03.331Z", "location_count": 9, "location_summary": "Peoria, Arizona • Daytona Beach, Florida • Port Orange, Florida + 5 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550355" }, { "nct_id": "NCT01732211", "title": "A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Sarcoidosis" ], "interventions": [ { "name": "PD 0360324", "type": "BIOLOGICAL" }, { "name": "Normal Saline for injection", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2013-03-15", "completion_date": "2013-09-23", "has_results": true, "last_update_posted_date": "2020-01-06", "last_synced_at": "2026-09-04T17:19:03.331Z", "location_count": 5, "location_summary": "New York, New York • Cincinnati, Ohio", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01732211" }, { "nct_id": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" }, { "name": "PF-04518600", "type": "DRUG" }, { "name": "PD 0360324", "type": "DRUG" }, { "name": "CMP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2015-11-09", "completion_date": "2023-03-23", "has_results": true, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-09-04T17:19:03.331Z", "location_count": 57, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02554812" }, { "nct_id": "NCT01470313", "title": "A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Lupus Erythematosus" ], "interventions": [ { "name": "PD-0360324", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 28, "start_date": "2011-11", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2014-01-29", "last_synced_at": "2026-09-04T17:19:03.331Z", "location_count": 17, "location_summary": "Anniston, Alabama • Oxford, Alabama • Los Angeles, California + 13 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Oxford", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange Park", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01470313" }, { "nct_id": "NCT02948101", "title": "PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Anti-CSF1 Monoclonal Antibody PD-0360324", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2018-12-31", "completion_date": "2019-02-06", "has_results": false, "last_update_posted_date": "2019-03-12", "last_synced_at": "2026-09-04T17:19:03.331Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02948101" } ] }